Cargando…

Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients

BACKGROUND: Valganciclovir, the oral prodrug of ganciclovir, has been demonstrated equivalent to iv ganciclovir for CMV disease treatment in solid organ transplant recipients. Variability in ganciclovir exposure achieved with valganciclovir could be implicated as a contributing factor for explaining...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perrottet, Nancy, Manuel, Oriol, Lamoth, Frédéric, Venetz, Jean-Pierre, Sahli, Roland, Decosterd, Laurent A, Buclin, Thierry, Pascual, Manuel, Meylan, Pascal
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820479/ https://www.ncbi.nlm.nih.gov/pubmed/20053269 http://dx.doi.org/10.1186/1471-2334-10-2

Ejemplares similares

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
por: Wong, Diana D., et al.
Publicado: (2022)

Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis
por: Vaziri, Siavash, et al.
Publicado: (2014)

Treatment of unilateral zone I cytomegalovirus retinitis in acute lymphoblastic leukemia with oral valganciclovir and intravitreal ganciclovir
por: Tripathy, Koushik, et al.
Publicado: (2017)

Treatment of cytomegalovirus anterior segment infection with intravitreal injection of ganciclovir in adjunction with or without oral valganciclovir: a long-term results
por: Cheng, Yu-Chun, et al.
Publicado: (2021)

1703. Hematologic Toxicity of Valganciclovir Prophylaxis in Solid Organ Transplant Recipients as a Function of Weight-adjusted Ganciclovir Exposure
por: Campanella, Toni A, et al.
Publicado: (2020)

Optimal Use of Ganciclovir and Valganciclovir in Transplanted Patients: How Does It Relate to the Outcome?
por: Mozaffar, Maryam, et al.
Publicado: (2018)

Valganciclovir—Ganciclovir Use and Systematic Therapeutic Drug Monitoring. An Invitation to Antiviral Stewardship
por: Galar, Alicia, et al.
Publicado: (2021)

Establishment and Evaluation of a Parametric Population Pharmacokinetic Model Repository for Ganciclovir and Valganciclovir
por: Yang, Wenyu, et al.
Publicado: (2023)

P1336: ANTIVIRAL EXPOSURE TO GANCICLOVIR AND VALGANCICLOVIR IS NOT ASSOCIATED WITH INCREASED INCIDENCE OF RELAPSE OR SECONDARY MALIGNANCIES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
por: Duarte, D., et al.
Publicado: (2022)

Use of letermovir‐valganciclovir combination as a step‐down treatment after foscarnet for ganciclovir‐resistant CMV infection in kidney transplant recipients
por: Rho, Elena, et al.
Publicado: (2021)

Ganciclovir-resistant cytomegalovirus infection in renal transplantation
por: Vaz, Raquel, et al.
Publicado: (2014)

Cytomegalovirus retinitis treated with valganciclovir in Wegener’s granulomatosis
por: Kabata, Yoshiaki, et al.
Publicado: (2012)

Late onset tacrolimus-induced life-threatening polyneuropathy in a kidney transplant recipient patient
por: Renard, Delphine, et al.
Publicado: (2012)

Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
por: Patil, A Jayaprakash, et al.
Publicado: (2010)

Treating HIV-associated cytomegalovirus retinitis with oral valganciclovir and intra-ocular ganciclovir by primary HIV clinicians in southern Myanmar: a retrospective analysis of routinely collected data
por: Murray, Jillian, et al.
Publicado: (2020)

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
por: Kim, Jong Man, et al.
Publicado: (2015)

1702. Assessing the Safety and Efficacy of Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients on Hemodialysis
por: Yee, Jason, et al.
Publicado: (2020)

Pediatric Dosing of Ganciclovir and Valganciclovir: How Model‐Based Simulations Can Prevent Underexposure and Potential Treatment Failure
por: Jorga, Karin, et al.
Publicado: (2018)

Ganciclovir/letermovir: Rebound Cytomegalovirus hepatitis, acquired resistance to ganciclovir and nephrotoxicity: case report
Publicado: (2020)

Ganciclovir-Resistant Cytomegalovirus Infection in a Kidney Transplant Recipient Successfully Treated with Foscarnet and Everolimus
por: Menghi, Viola, et al.
Publicado: (2016)

Molecular Detection and Genotyping of Human Cytomegalovirus in Kidney Transplant Recipients under Ganciclovir Prophylaxis in Iran
por: Behnezhad, Farzane, et al.
Publicado: (2022)

Comparison of Three Renal Function Formulas for Ganciclovir/Valganciclovir Dose Individualization in CMV-Infected Solid Organ Transplantation Patients Using a Population Approach
por: Lalagkas, Panagiotis Nikolaos, et al.
Publicado: (2023)

Ganciclovir-resistant CMV (GCV-R CMV) Infection Leads to Poor Clinical Outcomes and Economic Burden of Ganciclovir-resistant Cytomegalovirus Infection in Lung Transplant Recipients
por: Patel, Twisha, et al.
Publicado: (2017)

Safety of Valganciclovir 450 mg 3 Times Weekly for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients Requiring Hemodialysis
por: Ecabert, Danielle, et al.
Publicado: (2021)

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
por: Doesch, Andreas O, et al.
Publicado: (2012)

High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation
por: Rissling, Olesja, et al.
Publicado: (2018)

1146. Thrombocytosis in Infants with Congenital Cytomegalovirus Infection Being Treated with Valganciclovir
por: Murtagh, Kathleen, et al.
Publicado: (2020)

Presumed neonatal cytomegalovirus retinitis treated with intravenous ganciclovir
por: Suganya, A, et al.
Publicado: (2020)

Preemptive ganciclovir for mechanically ventilated patients with cytomegalovirus reactivation
por: Papazian, Laurent, et al.
Publicado: (2021)

A double masked randomised 4-week, placebo-controlled study in the USA, Thailand and Taiwan to compare the efficacy of oral valganciclovir and topical 2% ganciclovir in the treatment of cytomegalovirus anterior uveitis: study protocol
por: Takhar, Jaskirat S, et al.
Publicado: (2019)

Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next-Generation Sequencing
por: Lodding, Isabelle P, et al.
Publicado: (2021)

Ganciclovir therapeutic drug monitoring in transplant recipients
por: Märtson, Anne-Grete, et al.
Publicado: (2021)

Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation
por: Hashim, Faris, et al.
Publicado: (2014)

Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir
por: Ortiz-Gracia, Alba, et al.
Publicado: (2022)

Treatment outcomes of reduced-dose intravitreal ganciclovir for cytomegalovirus retinitis
por: Choopong, Pitipol, et al.
Publicado: (2016)

Ganciclovir penetrates into the cerebrospinal fluid of an infant with congenital cytomegalovirus infection
por: Natale, Fabio, et al.
Publicado: (2015)

Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients
por: Khurana, Mark P, et al.
Publicado: (2019)

1584. Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next-generation Sequencing
por: Lodding, Isabelle Paula, et al.
Publicado: (2018)

New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients
por: Åsberg, A, et al.
Publicado: (2014)

Correlation of cytomegalovirus viral load between whole blood and plasma of congenital cytomegalovirus infection under valganciclovir treatment
por: Torii, Yuka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o4v9aidd6df5juttea0c2b1trj